294.85
80,796.84
0.37%
Market Closed
1,431.1
0.64%
1,936.15
0.6%
11.35
3,455.15
0.36%
1,865.45
0.73%
1,428.75
-0.21%
-10.05
790
-1.26%
1,507.7
0.08%
8,932.5
0.79%
2,348.55
0.98%
6.95
437.1
1.62%
817.45
3.08%
3,328.35
0.11%
1,835.15
0.34%
2,085.05
-4.57%
1,569.1
-0.43%
12,464.05
0.44%
1,173.45
-0.64%
3,021.4
3.11%
11,661.25
0.11%
-0.25
348.55
-0.07%
2,025.4
3.73%
239.4
-1.64%
4,591.2
2.16%
3,314.85
-0.73%
308.55
1.68%
1,346.8
6.29%
2,452.7
6.96%
4,017.05
-0.95%
243.35
0.25%
661.6
1.5%
955.95
-1.76%
385.65
0.33%
2,437.3
1.18%
315.45
1.35%
240
2.45%
-6.4
2,330.4
-0.16%
7,918
0.93%
5,524.7
3.67%
556.2
5.96%
148.6
3.66%
2,752.25
1.09%
228.6
5,374.35
4.44%
428.4
0.18%
539.15
2.86%
1,770.05
0.24%
142.1
0.57%
6.8
693.65
0.8%
419.3
1.12%
125
0.68%
294.85
80796.84
0.37%
Market Closed

CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Aurobindo Pharma tanks post unprecedented move by USFDA
Amir Shaikh
/ Categories: Trending

Aurobindo Pharma tanks post unprecedented move by USFDA

Aurobindo Pharma on 21st February informed the bourses that it has received a follow-up communication from the U.S. Food and Drug Administration (USFDA), that the inspection conducted by the USFDA at Unit IV, from November 4, 2019 to November 13, 2019, is still open and under review, by way of rescindment of 90-day VAl letter that was issued by them on February 18, 2020. This move is unprecedented and now there is overhang on the company that it might face OAI for Unit-IV.

On 19th February the agency had issued Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAl) status. With this positive development the stock of Aurobindo Pharma had surged nearly 20 per cent but now with this under review status the stock in today's trading session has reacted negatively and tanked as much as 18 per cent to touch an intraday low of Rs 491.90.

Unit-IV of Aurobindo Pharma has the largest number of filings pending approval of 47 ANDAs.

Previous Article EPC agreement execution fails to lift shares of Dilip Buildcon
Next Article RPP Infra Projects zooms 10 per cent after bagging new order
Print
1038 Rate this article:
4.7
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR